Disc Medicine, Inc. (IRON)
- Previous Close
34.28 - Open
34.74 - Bid 34.52 x 100
- Ask 34.67 x 100
- Day's Range
33.56 - 36.38 - 52 Week Range
25.60 - 77.60 - Volume
600,520 - Avg. Volume
514,255 - Market Cap (intraday)
856.854M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.35 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.33
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
www.discmedicine.comRecent News: IRON
Performance Overview: IRON
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IRON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IRON
Valuation Measures
Market Cap
856.85M
Enterprise Value
516.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.37%
Return on Equity (ttm)
-28.23%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-80.6M
Diluted EPS (ttm)
-3.35
Balance Sheet and Cash Flow
Total Cash (mrq)
342.62M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
-51.57M